Cargando…

Identification of mutation patterns and circulating tumour DNA-derived prognostic markers in advanced breast cancer patients

BACKGROUND: The correlations between circulating tumour DNA (ctDNA)-derived genomic markers and treatment response and survival outcome in Chinese patients with advanced breast cancer (ABC) have not been extensively characterized. METHODS: Blood samples from 141 ABC patients who underwent first-line...

Descripción completa

Detalles Bibliográficos
Autores principales:	Liao, Hao, Zhang, Jiayang, Zheng, Tiantian, Liu, Xiaoran, Zhong, Jianxin, Shao, Bin, Dong, Xiaoxi, Wang, Xiaohong, Du, Pan, King, Bonnie L., Jia, Shidong, Yu, Jianjun, Li, Huiping
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2022
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9101837/ https://www.ncbi.nlm.nih.gov/pubmed/35562750 http://dx.doi.org/10.1186/s12967-022-03421-8

Ejemplares similares

Prognostic Value of the TP53 Mutation Location in Metastatic Breast Cancer as Detected by Next-Generation Sequencing
por: Bai, Han, et al.
Publicado: (2021)

Clinicopathologic features, genomic profiles and outcomes of younger vs. older Chinese hormone receptor-positive (HR+)/HER2-negative (HER2-) metastatic breast cancer patients
por: Wang, Jinhao, et al.
Publicado: (2023)

Efficacy and Safety of Initial 5 Years of Adjuvant Endocrine Therapy in Postmenopausal Hormone Receptor-Positive Breast Cancer: A Systematic Review and Network Meta-Analysis
por: Liao, Hao, et al.
Publicado: (2022)

The prognostic value of chemotherapy or endocrine therapy choice according to circulating tumor cell count in HR(+)HER2(−) metastatic breast cancer: a retrospective study
por: Shao, Bin, et al.
Publicado: (2022)

Germline Mutational Landscape in Chinese Patients With Advanced Breast Cancer
por: Zhang, Jiayang, et al.
Publicado: (2022)

Dynamic changes in gene alterations during chemotherapy in metastatic castrate resistant prostate cancer
por: Tan, Winston, et al.
Publicado: (2022)

Circulating Cell-Free DNA-Based Detection of Tumor Suppressor Gene Copy Number Loss and Its Clinical Implication in Metastatic Prostate Cancer
por: Dong, Xiaoxi, et al.
Publicado: (2021)

Gene Mutations in Circulating Tumour DNA as a Diagnostic and Prognostic Marker in Head and Neck Cancer—A Systematic Review
por: Hudečková, Markéta, et al.
Publicado: (2021)

Detection and Characterization of Circulating Tumour Cells in Multiple Myeloma
por: Zhang, Liangxuan, et al.
Publicado: (2016)

Prognostic Value of Pretreatment Neutrophil-to-Lymphocyte Ratio in HER2-Positive Metastatic Breast Cancer
por: Shao, Bin, et al.
Publicado: (2022)

Efficacy and safety of PEG-rhG-CSF versus rhG-CSF in preventing chemotherapy-induced-neutropenia in early-stage breast cancer patients
por: Jiang, Yantao, et al.
Publicado: (2023)

The prognostic value of neutrophil-to-lymphocyte ratio in de novo stage IV breast cancer: a retrospective cohort study
por: Shao, Bin, et al.
Publicado: (2023)

Circulating tumour-derived nucleic acids in cancer patients: potential applications as tumour markers
por: Chan, K C A, et al.
Publicado: (2007)

Postoperative circulating tumor DNA detection and CBLB mutations are prognostic biomarkers for gastric cancer
por: Zhou, Hekai, et al.
Publicado: (2023)

REporting recommendations for tumour MARKer prognostic studies (REMARK)
por: McShane, L M, et al.
Publicado: (2005)

REporting recommendations for tumour MARKer prognostic studies (REMARK)
por: Harris, A L
Publicado: (2005)

Direct comparison study of DNA methylation markers in EpCAM-positive circulating tumour cells, corresponding circulating tumour DNA, and paired primary tumours in breast cancer
por: Chimonidou, Maria, et al.
Publicado: (2017)

Clinical significance of circulating tumour cells and tumour marker detection in the chemotherapeutic evaluation of advanced colorectal cancer
por: Shen, Feifei, et al.
Publicado: (2021)

Detection and prognostic role of heterogeneous populations of melanoma circulating tumour cells
por: Aya-Bonilla, Carlos Alberto, et al.
Publicado: (2020)

Clinical and genomic insights into circulating tumor DNA-based alterations across the spectrum of metastatic hormone-sensitive and castrate-resistant prostate cancer
por: Kohli, Manish, et al.
Publicado: (2020)

Circulating Tumour DNA Is an Independent Prognostic Biomarker for Survival in Metastatic BRAF or NRAS-Mutated Melanoma Patients
por: Herbreteau, Guillaume, et al.
Publicado: (2020)

Diagnostic technologies for circulating tumour cells and exosomes
por: Shao, Huilin, et al.
Publicado: (2016)

Quantitative Acetylome Analysis of Differentially Modified Proteins in Virulence-Differentiated Fusarium oxysporum f. sp. cucumerinum Isolates during Cucumber Colonization
por: Zhou, Ying, et al.
Publicado: (2023)

Serum Metallothioneins in Childhood Tumours—A Potential Prognostic Marker
por: Kruseova, Jarmila, et al.
Publicado: (2013)

Prognostic Markers within the Tumour Microenvironment in Classical Hodgkin Lymphoma
por: Martynchyk, Arina, et al.
Publicado: (2023)

Molecular markers in circulating tumour cells from metastatic colorectal cancer patients
por: Gazzaniga, Paola, et al.
Publicado: (2010)

Plasma Epstein–Barr virus DNA as an archetypal circulating tumour DNA marker
por: Lam, Wai Kei Jacky, et al.
Publicado: (2019)

Analysis of Circulating Tumour Cells in Early-Stage Uveal Melanoma: Evaluation of Tumour Marker Expression to Increase Capture
por: Beasley, Aaron B., et al.
Publicado: (2021)

Long-term prognostic impact of circulating tumour cells in gastric cancer patients
por: Ito, Hiroaki, et al.
Publicado: (2016)

Year of Expanding into Circulating Biomarkers
por: Jia, Shidong, et al.
Publicado: (2015)

Prognostic value of absolute quantification of mutated KRAS in circulating tumour DNA in lung adenocarcinoma patients prior to therapy
por: Wahl, Sissel Gyrid Freim, et al.
Publicado: (2021)

Cell-free DNA comparative analysis of the genomic landscape of first-line hormone receptor-positive metastatic breast cancer from the US and China
por: Liu, Xiaoran, et al.
Publicado: (2021)

Impact of homologous recombination deficiency biomarkers on outcomes in patients with early breast cancer: a systematic review protocol
por: Liao, Hao, et al.
Publicado: (2022)

Marker genes for circulating tumour cells predict survival in metastasized breast cancer patients
por: Weigelt, B, et al.
Publicado: (2003)

Circulating immune complexes as markers of response to chemotherapy in malignant teratomas and gestational trophoblastic tumours.
por: Begent, R. H., et al.
Publicado: (1982)

Circulating tumour markers can define patients with normal colons, benign polyps, and cancers
por: Mead, R, et al.
Publicado: (2011)

Prognostic value of circulating tumour DNA in patients undergoing curative resection for pancreatic cancer
por: Hadano, Naoto, et al.
Publicado: (2016)

Longitudinal monitoring of circulating tumour DNA improves prognostication and relapse detection in gastroesophageal adenocarcinoma
por: Openshaw, Mark R., et al.
Publicado: (2020)

Circulating Tumour Cell Expression of Immune Markers as Prognostic and Therapeutic Biomarkers in Head and Neck Squamous Cell Carcinoma: A Systematic Review and Meta-Analysis
por: Payne, Karl, et al.
Publicado: (2020)

Efficacy of apatinib 250 mg combined with chemotherapy in patients with pretreated advanced breast cancer in a real-world setting
por: Zhang, Ruyan, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_mkhoinnou4lpcs9r7uk2bnln7t